Drug Search Results

Leteprinim

Alternative Names: leteprinim, ait-082, ait082, ait 082, neotrofin
Latest Update: 2023-04-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Assertio Holdings
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peripheral Nervous System Diseases|Chemotherapy-induced Peripheral Neuropathy

Phase 1: Memory Disorders

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
IA0008	P1	Completed	Memory Disorders	2005-06-01
NCT00041795	P2	Completed	Peripheral Nervous System Diseases\|Chemotherapy-induced Peripheral Neuropathy	None

Recent News Events

Date	Type	Title
04/04/2023	PubMed	Negative and positive allosteric modulators of the α7 nicotinic acetylcholine receptor regulates the ability of adolescent binge alcohol exposure to enhance adult alcohol consumption.
09/01/2020	PubMed	Regulation of the deleterious effects of binge-like exposure to alcohol during adolescence by α7 nicotinic acetylcholine receptor agents: prevention by pretreatment with a α7 negative allosteric modulator and emulation by a α7 agonist in alcohol-preferring (P) male and female rats.
07/01/2020	PubMed	FMRP Regulates the Nuclear Export of Adam9 and Psen1 mRNAs: Secondary Analysis of an N6-Methyladenosine Dataset.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions